Zuranolone Treatment for Depression: Steady Progress in Mechanism-Focused Therapeutics?

Affiliations

Editorial

Daniel S Pine. Am J Psychiatry. 2023.

. 2023 Sep 1;180(9):631-633.

doi: 10.1176/appi.ajp.20230537.

¹ Ross Center, Washington, D.C.; National Institute of Mental Health, Bethesda, Md.

No abstract available

Keywords: Biological Markers; Biomarkers; Depression; Depressive Disorders; Psychopharmacology.

Comment on

Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
Clayton AH, Lasser R, Parikh SV, Iosifescu DV, Jung J, Kotecha M, Forrestal F, Jonas J, Kanes SJ, Doherty J. Clayton AH, et al. Am J Psychiatry. 2023 Sep 1;180(9):676-684. doi: 10.1176/appi.ajp.20220459. Epub 2023 May 3. Am J Psychiatry. 2023. PMID: 37132201 Clinical Trial.
Zuranolone for the Treatment of Postpartum Depression.
Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N, Garcia M, Leclair B, Doherty J. Deligiannidis KM, et al. Am J Psychiatry. 2023 Sep 1;180(9):668-675. doi: 10.1176/appi.ajp.20220785. Epub 2023 Jul 26. Am J Psychiatry. 2023. PMID: 37491938 Clinical Trial.